Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power…
Search Posts
Newsletter
The Fed, Biotech Crops and Mortgage Bailouts
Treasury Secretary Henry Paulson officially announces a plan to reform oversight of financial markets. Research into genetically modified crops gets a boost in India. President…
Newsletter
Sarbanes-Oxley, Cancer Drugs and Discrimination Law
The National Law Journal warns that penalties in the Sarbanes-Oxley accounting rules for public companies can extend to individuals and private entities. Drug maker Cephalon…
Study
The Five Dumbest Product Bans
This paper focuses on five clearly absurd product bans that seem to serve no social good.
Newsletter
CEI Daily Update
1. ENVIRONMENT CEI releases a new video contrasting increasing carbon dioxide levels with global temperatures. CEI Expert Available to Comment: Senior Fellow…
Newsletter
CEI Daily Update
Issues in the News 1. ENVIRONMENT Sen. Dianne Feinstein (D-CA) pressures the Environmental Protection Agency to declare carbon dioxide a pollutant. CEI Expert Available…
News Release
Supreme Court Rulings Good for Investors
Washington, D.C., February 20, 2008—The Supreme Court this session has made two important decisions that will greatly benefit investors. Both today’s ruling in LaRue v.